Nature against depression

Current Medicinal Chemistry

Volumn 19, Issue 14, 2012, Pages 2229-2241

  El Alfy, A T ^a   Abourashed, E A ^a   Matsumoto, R R ^b  

^a CHICAGO STATE UNIVERSITY   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Chemical constituents; Clinical trials; Depression; Herbal medicines.

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BANXIA HOUPU; CANNABIS; DIAZEPAM; DIGOXIN; DOPAMINE; ECHIUM EXTRACT; FORMULA SYJN; GAN MAI DA ZAO; HERBACEOUS AGENT; HYPERFORIN; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; INDINAVIR; LAVENDER OIL; MIDAZOLAM; NORADRENALIN; PLACEBO; PLANT EXTRACT; POLYGALA TENUIFOLIA EXTRACT; RHODIOLA ROSEA EXTRACT; SAFFRON EXTRACT; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; WARFARIN;

ALLERGIC REACTION; ALTITUDE DISEASE; ANTIOXIDANT ACTIVITY; ARTICLE; CHRONIC STRESS; CLINICAL TRIAL (TOPIC); CRASSULACEAE; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; ECHIUM; EMOTIONAL DISORDER; FATIGUE; GASTROINTESTINAL DISEASE; HEADACHE; HERBAL MEDICINE; HUMAN; HYPERICACEAE; HYPERICUM PERFORATUM; INSOMNIA; LAVANDULA ANGUSTIFOLIA; LAVENDER; LIPID PEROXIDATION; MAJOR DEPRESSION; META ANALYSIS; MULTICENTER STUDY (TOPIC); NATURAL SCIENCE; NONHUMAN; PHOTOSENSITIVITY; PLANT ROOT; POLYGALA TENUIFOLIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHODIOLA; SIDE EFFECT;

EID: 84860661296     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712800229096     Document Type: Article

References (145)

1. Berton, O.; Nestler, E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat. Rev. Neurosci., 2006, 7, 137-151. (Pubitemid 43151600)
2. World Health Organization. http://www.who.int/mental-health/management/ depression/definition/en/(Accessed September 30, 2011).
3. Stewart, W.; Ricci, J.A.; Chee, E.; Hahn, S.R.; Morganstein, D. Cost of lost productive work time among US workers with depression. JAMA, 2003, 289, 3135-3144. (Pubitemid 37432889)
4. Mann, J.J. The medical management of depression. N. Eng. J. Med., 2005, 353, 1819-1834.
5. Stahl, S. Essential Psychopharmacology of Depression and Bipolar Disorder, Cambridge University Press, 2000.
6. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision, DSM-IV-TRTM. American Psychiatric Asscoiation, 2000.
7. International Statistical Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), 2011.
8. Chang, T.; Fava, M. The future of psychopharmacology of depression. J. Clin. Psychiatry, 2010, 71, 971-975.
9. Covington, H.E. III; Vialou, V.; Nestler, E.J. From synapse to nucleus: Novel targets for treating depression. Neuropharmacology, 2010, 58, 683-693.
10. Fishback, J.A.; Robson, M.J.; Xu, Y.-T.; Matsumoto, R.R. Sigma receptors: Potential targets for a new class of antidepressant drug. Pharmacol. Ther., 2010, 127, 271-282.
11. Rush, A.J.; Trivedi, M.H.; Wisniewski, S.R.; Nierenberg, A.A.; Stewart, J.W.; Warden, D.; Niederehe, G.; Thase, M.E.; Lavori, P.W.; Lebowitz, B.D.; McGrath, P.J.; Rosenbaum, J.F.; Sackeim, H.A.; Kupfer, D.J.; Luther, J.; Fava, M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A Star.*D report. Am. J. Psychiatry, 2006, 163, 1905-1917. (Pubitemid 44807782)
12. Dwyer, A.V.; Whitten, D.L.; Hawrelak, J.A. Herbal medicines, other than St. John's wort, in the treatment of depression: A systematic review. Alt. Med. Rev., 2011, 16, 40-49.
13. Sarris J, Panossian A, Schweitzer I, Stough C, Scholey A. Herbal medicine for depression, anxiety and insomnia: A review of psychopharmacology and clinical evidence. Eur. Neuropsychopharmacol., 2011, [Epub ahead of print-PMID:21601431].
14. Mostert, J.P.; Koch, M.W.; Heerings, M.; Heersema, D.J.; De Keyser, J. Therapeutic potential of fluoxetine in neurological disorders. CNS Neurosci. Ther., 2008, 14, 153-164. (Pubitemid 351713316)
15. Papakostas, G.I.; Thase, M.E.; Fava, M.; Nelson, J.C.; Shelton, R.C. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol. Psychiatry, 2007, 62, 1217-1227. (Pubitemid 350060895)
16. Schulz, V. Safety of St. John's wort extract compared to synthetic antidepressants. Phytomedicine, 2006, 13, 199-204. (Pubitemid 43120322)
17. Madabushi, R.; Frank, B.; Drewelow, B.; Derendorf, H.; Butterweck, V. Hyperforin in St. John's wort drug interactions. Eur. J. Clin. Pharmacol., 2006, 62, 225-233. (Pubitemid 43357581)
18. Khan, I.A.; Abourashed, E.A. Leung's Encyclopedia of Common Natural Ingredients Used in Foods, Drugs and Cosmetics, 3rd ed., Wiley, New Jersey, 2009, pp. 371-4.
19. Laakmann, G.; Trautmann-Sponsel, R.D.; Kieser, M. St John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry, 1998, 31(Suppl), 54-59. (Pubitemid 28294226)
20. Blumenthal, M.; The ABC Clinical Guide to Herbs; Thieme, New York, 2003, p. 324.
21. German Federal Health Office (BGA) Monograph; Hyperica herba (St. John's wort) Commision E monograph. Bundesanzeiger, 1984 Dec. 5.
22. Linde, K.; Berner M.M., Kriston, L. St John's wort for major depression. Cochrane Database Sys. Rev., 2008, 4, CD000448.
23. Rahimi, R.; Nikfar, S.; Abdollahi, M. Efficacy and tolerability of Hypericum perforatum in major depressive disorders in comparison with selective serotonin reuptake inhibitors: a meta-analysis. Prog. Neuropychopharmacol. Biol. Psychiatry, 2009, 33, 118-127.
24. Whiskey, E.; Werneke, U.; Taylor, D.A. A systematic review and meta analysis of Hypericum Perforatum in depression: a comprehensive clinical review. Int. Clin. Psychopharmacol., 2001, 16, 239-252. (Pubitemid 32822443)
25. Kim H.L.; Streltzer, J.; Goebert, D. St. John's wort for depression: a meta analysis of well-defined clinical trials. J. Nerv. Ment. Dis., 1999, 187, 532-538. (Pubitemid 29449009)
26. Kasper, S.; Gastpar, M.; Muller, W.E.; Volz, H.P., Dienel, A.; Kieser, M.; Möller, H.J. Efficacy of St. John's wort extract WS5570 in acute treatment of mild depression. A reanalysis of data from controlled clinical trials. Eur. Arch. Psychiatry Clin. Neurosci., 2007, 258, 59-63. (Pubitemid 351208250)
27. Roder, C.; Schaefer, M.; Leucht, S. Meta-analysis of effectiveness and tolerability of treatment of mild to moderate depression with Sr. John's wort. Fortschr. Neurol. Psychiatr., 2004, 72, 330-343. (Pubitemid 38828820)
28. Kasper, S.; Anghelescu, I.; Szegedi, A.; Dienel, A.; Kieser, M. Superior efficacy of St. John's wort extract WS® 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]. BMC Medicine, 2006, 4(14), 1-13.
29. Kalb, R.; Trautmann-Sponsel, R.D.; Keiser, M. Efficay and tolerability of Hypericum extract WS5572 versus placebo in mildly to moderately depressed patients. Pharmacopsychiatry, 2001, 34, 96-103.
30. Schrader, E.; Meier, B.; Brattstrom, A. Hypericum treatment of mildmoderate depression in a placebo-controlled study. A prospective, doubleblind, randomized, placebo-controlled, multicentre study. Hum. Psychopharmacol., 1998, 13, 163-169. (Pubitemid 28216247)
31. Sommer, H.; Harrer, G. Placebo-controlled double-blind study examining the effectiveness of a Hypericum preparation in 105 mildly depressed patients. J. Geriatr. Psychiatry Neurol., 1994, 7(Suppl), 9-11.
32. Gaster, B.; Holroyd, J. St. John's wort for depression. Arch. Intern. Med., 2000, 160, 152-156.
33. Linde, K.; Ramirez, G.; Mulrow, C.D.; Pauls, A.; Weldenhammer, W.; Melchart, D. St. John's wort for depression: an overview and met-analysis of randomized clinical trials. BMJ, 1996, 313, 253-258. (Pubitemid 26254730)
34. Linde, K.; Mulrow, C.D. St. John's wort for depression [Cochrane Database of Systemic Reviews]. Oxford, England: Cochrane Library, 2000, issue 2.
35. Carpenter, D.J. St. John's wort and S-adenosyl methionine as "natural" alternatives to conventional antidepressant in the era of the suicidality boxed warning: what is the evidence for clinically relevant benefit? Alt. Med. Rev., 2011, 16(1), 17-39.
36. Shelton, R.C.; Keller, M.B.; Gelenberg, A.; Dunner, D.L.; Hirschfeld, R.; Thase, M.E.; Russell, J.; Lydiard, R.B.; Crits-Christoph, P.; Gallop, R.; Todd, L.; Hellerstein, D.; Goodnick, P.; Keitner, G.; Stahl, S.M.; Halbreich, U. Effectiveness of St. John's wort in major depression: A randomized controlled trial. JAMA, 2001, 285(15), 1978-1986. (Pubitemid 32366950)
37. Knupple, L.; Linde, K. Adverse effects of St John's wort: a systematic review. J. Clin. Psychiatry, 2004, 65, 1470-1479.
38. Sculz, V. Safety of St John's wort extract compared to synthetic antidepressants. Phytomedicine, 2006, 13, 199-204.
39. Rodriguez-Landa, J.F.; Contreras, C.M. A review of clinical and experimental observations about antidepressant actions and side effects produced by Hypericum perforatum extracts. Phytomedicine, 2003, 10, 688-699. (Pubitemid 37500099)
40. Zhou, S.F.; Lai, X. An update on clinical drug interactions with the herbal antidepressant St. John's wort. Curr. Drug. Metab., 2008, Jun 9(5), 394-409. (Pubitemid 352025194)
41. Chen, X.W.; Serag, E.S.; Sneed, K.B.; Liang, J.; Chew, H.; Pan, S.Y.; Zhou, S.F. Clinical herbal interactions with conventional drugs: from molecules for maladies. Curr. Med. Chem., 2011, Sep 15 (PMID 21919844).
42. Borrelli, F.; Izzo, A.A. Herb-drug interactions with St Jonh's wort (Hypericum perforatum): an update on clinical observations. The AAPS Journal, 2009, 11(4), 710-727.
43. Suzuki, O.; Katsumata, Y; Oya, M.; Bladt, S.; Wagner, H. Inhibition of monoamie oxidase by hypericin. Planta Med., 1984, 50, 272-274.
44. Thiede, H.M.; Walper, A. Inhibition of MAO an dCOMT by hypericum extracts and hypericin. J. Geriatr. Psychiatry Neurol., 1994, 7(Suppl 1), S54-56. (Pubitemid 24330533)
45. Bladt, S.; Wagner, H. Inhibition of MAO by fractions and constituents of hypericum extract. J. Geriatr. Psychiatry Neurol., 1994, 7(Suppl 1), S57-59. (Pubitemid 24330534)
46. Butterweck, V. Mechanism of action of St. John's wort in depression: what is known? CNS Drugs, 2003, 17, 539-562. (Pubitemid 36774135)
47. Muller, W.E. Current St. John's wort research from mode of action to clinical efficacy. Pharmacol. Res., 2003, 47, 101-109. (Pubitemid 36263444)
48. Butterweck, V.; Bockers, T.; Korte, B.; Wittowski, W.; Winterhoff, H. Long term effects of St. John's wort and hypericin on monoamine levels in the rat hypothalamus and hippocampus. Brain Res., 2002, 930, 21-29. (Pubitemid 34195624)
49. Butterweck, V.; Korte, B.; Winterhoff, H. Pharmacological and endocrine effects of Hypericum perfortau and hypericin after repeated treatment. Pharmacopsychiatry, 2001, 34(Suppl), 2-7.
50. Butterweck, V.; Winterhoff, H.; Herkenham, M. St John's wort, hypericin, and imipramine: a comparative analysis of mRNA levels in brain areas involved in HPA axis control following short-term and long-term administration in normal and stressed rats. Mol. Psychiatry, 2001, 6, 547-564. (Pubitemid 32772564)
51. Hunt, E.J.; Lester, C.E.; Lester, E.A.; Tackett, R.L. Effect of St. John's wort on free radical production. Life Sci., 2001, 1; 69(2), 181-190. (Pubitemid 32523074)
52. Kumar, A.; Garg, R.; Prakash, A.K. Effect of St. John's wort (Hypericum perforatum) treatment on restraint-induced behavioral and biochemical alteration in mice. BMC Compl. Altern. Med., 2010, 10(18), 1-6.
53. McCue, P.P.; Phang, J.M. Identification of human intracellular targets of the medicinal herb St. John's wort by chemical-genetic profiling in yeaSt. J. Agric. Food Chem., 2008, 56(22), 11011-11017.
54. Khan, I.A.; Abourashed, E.A. Leung's Encyclopedia of Common Natural Ingredients Used in Foods, Drugs and Cosmetics, 3rd ed., Wiley, New Jersey, 2009, pp. 547-549.
55. Noorbala, A.A.; Akhondzadeh, S.; Tahmacebi-Pour, N.; Jamshidi, A.H. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. J. Ethnopharmacol., 2005, 97(2), 281-284. (Pubitemid 40222030)
56. Basti, A.; Moshiri, E.; Noorbala, A.A.; Jamshidi, A.H.; Abbasi, S.H.; Akhondzadeh, S. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outapatients: a pilot double-blind randomized trial. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31(2), 439-442. (Pubitemid 46209441)
57. Rios, J.L.; Recio, M.C.; Giner, R.M.; Manez, S. An update review of saffron and its active constituents. Phytother. Res., 1996, 10, 189-193. (Pubitemid 26164562)
58. Akhondzadeh, S.; Tahmecebi-Pour, N.; Noobala, A.; Amini, H.; Fallah-Pour, H.; Jamshidi, A.; Khani, M. Crocus sativus L. in the treatment of mild to moderate depression: A double-blind, randomized and placebo-controlled trial. Phytother. Res., 2005, 19, 148-151. (Pubitemid 40646420)
59. Moshiri, E.; Basti, A.A.; Norbala, A.A.; Jamshidi, A.H.; Hesameddin Abbasi, S.; Akhondzadeh, S. Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: a double-blind, randomized and placebocontrolled trial. Phytomedicine, 2006, 13(9-10), 607-611. (Pubitemid 44666407)
60. Wang, Y.; Han, T.; Zhu, Y.; Zheng, C.J.; Ming, Q.L.; Rahman, K.; Qin, L.P. Antidepressant properties of bioactive fractions from the extract of Crocus sativus L. J. Nat. Med., 2010, 64(1), 24-30.
61. Berger, F.; hensel, A.; Nieber, K. Saffron extract and trans-crocetin inhibit glutamatergic synaptic transmission in rat cortical brain slices. Neuroscience, 2011, 180, 238-247.
62. Panossian, A.; Wikman, G.; Sarris, J. Roseroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy. Phytomedicine, 2010, 481-493.
63. Khanum, F.; Bawa, A.S.; Singh, B. Rhodiola rosea: a versatile adaptogen. Compr. Rev. Food Sci. Food Saf., 2005, 4, 55-62. (Pubitemid 44402011)
64. Petkov, V.D.; Yonkov, D.; Mosharoff, A.; Kambourova, T.; Petkov, V.V.; Todorov, I. Effects of alcohol aqueous extract from Rhodiola rosea L. roots on learning and memory. Acta. Pysiol. Pharmacol. Bulg., 1986, 12(1), 3-16.
65. Sarris, J. Herbal medicines in the treatment of psychiatric disorders: a systematic review. Phytother. Res., 2007, 21, 703-716. (Pubitemid 47217768)
66. Darbinyan, V.; Aslanyan, G.; Amroyan, E.; Gabrielyan, E.; Malmstrom, C.; Panossian, A. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nord. J. Psychiatry, 2007, 61(5), 343-348. (Pubitemid 350091013)
67. Olsson, E.M.; von Scheele, B.; Panossian, A.G. A randomized, double-blind, placebo-controlled, parallel-group study of the standardized extract SHR-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue. Planta Med., 2009, 75(2), 105-112.
68. Panossian, A.; Hovhannisyan, A.; Abrahamyan, H.; Gabrielyan, E.; Wikman, G. Pharmacokinetic and pharmacodynamic study of interaction of Rhodila rosea SHR-5 extract with warfarin and theophylline in rats. Phytother. Res., 2009, 23, 351-357.
69. Perfumi, M.; Mattioli, L. Adaptogenic and central nervous system effects of single doses of 3% rosavin and 1% salidroside Rhodiola rosea L. extract in mice. Phytother. Res., 2007, 21, 37-43. (Pubitemid 46173906)
70. Panossian, A.; Nikoyan, N.; Ohanyan, N.; Hovhannisyan, A.; Abrahamyan, H.; Gabrielyan, E.; Wikman, G. Comparative study of Rhodiola preparations on behavioral despair of rats. Phytomedicine, 2008 Jan, 15(1-2), 84-91.
71. Mattioli, L.; Funari, C.; Perfumi, M. Effects of Rhodiola rosea L. extract on behavioral and physiological alterations induced by chronic mild stress in female rats. J. Psychopharmacol., 2009, 23(2), 130-142.
72. Kurkin, V.A.; Zapesochnaya, G.G. Chemical composition and pharmacological properties of Rhodiola rosea. Khim. Pharm. Zurnal., 1986, 20, 1231-1244.
73. Stancheva, S.L.; Mosharrof, A. Effect of the extract of Rhodiola rosea L. on the content of the brain biogenic amines. Med. Physiol., 1987, 40, 85-87.
74. Panossian, A.; Wagner, H. Stimulating effect of adaptogens: an overview with particular reference to their efficacy following single dose administration. Phytother. Res., 2005, 19. 819-838. (Pubitemid 41670526)
75. Qin, Y.Z.; Zeng, Y.S.; Zhou, C.C.; Zhong, Z.Q. Effects of Rhodiola rosea on level of 5-hydroxytryptamine, cell proliferation and differentiation, and number of neurons in cerebral hippocampus of rats with depression induced by chronic mild stress. Zhongguo Zhong Yao Za Zhi, 2008, 33(23), 2842-2846.
76. Chen, Q.G.; Zeng, Y.S.; Qu, Z.Q.; Tang, J.Y.; Qin, Y.J.; Chung, P.; Wong, R.; Hägg, U. The effects of Rhodiola rosea extract on 5-HT level, cell proliferation and quantity of neurons at cerebral hippocampus of depressive rats. Phytomedicine, 2009, 16(9), 830-838.
77. Khan, I.A.; Abourashed, E.A. Leung's Encyclopedia of Common Natural Ingredients Used in Foods, Drugs and Cosmetics, 3rd ed., Wiley, New Jersey, 2009, pp. 406-410.
78. Fakhari, A.R.; Salehi, P.; Heydari, R.; Ebrahimi, S.N.; Haddad, P.R. Hydrodistillation-headspace solvent microextraction, a new method for analysis of the essential oil components of Lavendula angustifolia Mill. J. Chromatogr. A, 2005, 1098, 14-18. (Pubitemid 41682404)
79. Cavanagh, H.M.A.; Wilkinson, J.M. Biological activities of lavender essential oil. Phytother. Res., 2002, 16, 301-308. (Pubitemid 34700264)
80. Graham, C. Complementary therapies: In the scent of a good night's sleep. Nurs. Stand., 1995, 9, 21.
81. Dunn, C.; Sleep, J.; Collett, D. Sensing an improvement: an experimental study to evaluate the use of aromatherapy, massage, and periods of rest in an intensive care unit. J. Adv. Nurs., 1995, 21, 34-40.
82. Walsh, E.; Wilson, C. Complementary therapies in long-stay neurology inpatients settings. Nurs. Stand., 1999, 13, 32-35.
83. Alaoui-Ismaili, O.; Vernet-Maury, E.; Dittmar, A.; Delhomme, G.; Chanel, J. Odor hedonics: connection with emotional response estimated by autonomic parameters. Chem. Senses, 1997, 22, 237-248. (Pubitemid 27246256)
84. Akhondzadeh, S.; Kashani, L.; Fotouhi, A.; Jarvandi, S.; Mobaseri, M.; Khani, M.; Jamshidi, A.H.; Baghalian, K.; Taghizadeh, M. Comparison of Lavandula angustifolia Mill. tincture and imipramine in the treatment of mild to moderate depression: a double-blind, randomized trial. Pro.g Neuropsychopharmacol. Biol. Psychiatry, 2003, 27(1), 123-127. (Pubitemid 36126653)
85. Lim, W.C.; Seo, J.M.; Lee, C.I.; Pyo, H.B.; Lee, B.C. Stimulative and sedative effects of essential oils upon inhalation in mice. Arch. Pharm. Res., 2005, 28(7), 770-774.
86. Umezu, T. Behvaioral effects of plant0derived essential oils in the Geller Type conflict test in mice. Jpn. J. Pharmacol., 2000, 83, 150-153. (Pubitemid 30449744)
87. Kim, Y.; Kim, M; Kim, H. Effect of lavender oil on motor function and dopamine receptor expression in the olfactory bulb of mice. J. Ethnopharmacol., 2009, 125(1), 31-35.
88. Mehrabani, M.; Ghassemi, N.; Sajjadi, E.; Ghannadi, A.; Shams-Ardakani, M. Main phenolic compound of petals of Echium amoenum Fisch. And C.A. Mey., a famous medicinal plant of Iran. DARU J. Pharm. Sci., 2005, 13, 65-69. (Pubitemid 41297456)
89. Mehrabani, M.; Ghannadi, A.; Sajjadi, E.; Ghassemi, N.; Shams-Ardakani, M. Toxic pyrrolizidine alkaloids of Echium amoenum Fisch. & Mey. DARU J. Pharm. Sci., 2006, 14, 122-127. (Pubitemid 44808344)
90. Ghassemi, N.; Sajjadi, S.E.; Ghannadi, A.R.; Shams-Ardakani, M.; Mehrabani, M. DARU J. Pharm. Sci., 2003, 11(1), 32-33.
91. Ranjbar, A.; Khorami, S.; Safaradabi, M.; Shahmoradi, A.; Malekirad, A.A.; Vakilian, K.; Mandegary, A.; Abdollahi, M. Antioxidant activity of Iranian Echium amoenum Fisch and C.A. Mey flower decocotion in humans: a crosssectional before/after clinical trial. eCAM 2006, 3(4), 469-473. (Pubitemid 44899984)
92. Sayyah, M.; Sayyah, M.; Kamalinejad, M. A preliminary randomized double blind clinical trial on the efficacy of aqueous extract of Echium amoenum in the treatment of mild to moderate major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2006, 30(1), 166-169. (Pubitemid 43021340)
93. Kurata, K.; Tai, T.; Yang, Y.; Kinoshita, K.; Koyama, K.; Takahashi, K.; Watanabe, K.; Nunoura, Y. Quantitative analysis of anti-emetic principle in the tubers of Pinellia ternata by enzyme immunoassay. Phytochem. Anal., 1998, 64(7), 645-648. (Pubitemid 28481479)
94. Nagai, T.; Kiyohara, H.; Munakata, K.; Shirahata, T.; Sunazuka, T.; Harigaya, Y.; Yamada, H. Pinellic acid from the tuber of Pinellia ternata Breitenbach as an effective oral adjuvant for nasal influenza vaccine. Int. Immunopharmacol., 2002, 2(8), 1183-1193.
95. Chen, J.H.; Cui, G.Y.; Liu, J.Y.; Tan, R.X. Pinelloside, an antimicrobial cerebroside from Pinellia ternata. Phytochemistry, 2003, 64(4), 903-906. (Pubitemid 37267578)
96. Khan, I.A.; Abourashed, E.A. Leung's Encyclopedia of Common Natural Ingredients Used in Foods, Drugs and Cosmetics, 3rd ed., Wiley, New Jersey, 2009, pp. 508-510.
97. Chen, Y.-Y.; Chang, H.-M. Antiproliferative and differentiating effects of polysaccharide fraction from fu-ling (Poria cocos) on human leukemic U937 and HL-60 cells. Food Chem. Toxicol., 2004, 42(5), 759-769. (Pubitemid 38376343)
98. Xu, Q.; Yi, L.-T.; Pan, Y.; Wang, X.; Li, Y.-C.; Wang, C.-P.; Kong, L.-D. Antidepressant-like effects of the mixture of honokiol and magnolol from the barks of Magnolia officinalis in stressed rodents. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32(3), 715-25. (Pubitemid 351312371)
99. Makino, T.; Furuta, Y.; Fuji, H.; Nagakawa, T.; Wakushima, H.; Saito, K.; Kano, Y. Effect of oral treatment of Perilla frutescens and its constituents on type-I allergy in mice. Biol. Pharmacol. Bull., 2001, 24(10), 1206-1209. (Pubitemid 33049091)
100. Ueda, H.; Yamazaki, C.; Yamazaki, M. Luteolin as an anti-inflammatory and anti-allergic constituent of Perilla frutescens. Biol. Pharmacol. Bull., 2002, 25(9), 1197-1202. (Pubitemid 39655163)
101. Banno, N.; Akihisa, T.; Tokuda, H.; Yasukawa, K.; Higashihara, H.; Ukiya, M.; Watanabe, K.; Kimura, Y.; Hasegawa, J.; Nishino, H. Triterpene acids from the leaves of Perilla frutescens and their anti-inflammatory and antitumor-promoting effects. Biosci. Biotechnol. Biochem., 2004, 68(1), 85-90. (Pubitemid 39251568)
102. Khan, I.A.; Abourashed, E.A. Leung's Encyclopedia of Common Natural Ingredients Used in Foods, Drugs and Cosmetics, 3rd ed., Wiley, New Jersey, 2009, pp. 320-324.
103. Bo, P.; Chen, Q.M.; Zhu, H.H.; Zhang, X.D.; Xu, H.R.; Zhang, Y.; Cao, Y.J. Clinical observations on 46 cases of glubus hystericus treated with modified Banxia houpu decoction. J. Trad. Chin. Med., 2010, 30(2), 103-107.
104. Luo, L.; Nong Wang, J.; Kong, L.D.; Jiang, Q.G.; Tan, R.X. Antidepressant effects of Banxia Houpu decoction, a traditional Chinese medicinal empirical formula. J. Ethnopharmacol., 2000, 73(1-2), 277-281.
105. Guo, Y.; kong, l.; Wang, Y.; Huang, Z. Antidepressant evaluation of polysaccharides from a Chinese herbal medicine Banxia-houpu decoction. Phytother. Res., 2004, 18, 204-207. (Pubitemid 38568746)
106. Wang, Y.; Kong, L.; Chen, Y. Behavioral and biochemical effects of fractions prepared from Banxia houpu decoction in depression models of mice. Phytother. Res., 2005, 19, 526-529. (Pubitemid 41345531)
107. Li, J.M.; Kong, L.D.; Wang, Y.M.; Cheng, C.H.; Zhang, W.Y.; Tan, W.Z. Behavioral and biochemical studies on chronic mild stress models in rats treated with a Chinese traditional prescription Banxia-houpu decoction. Life Sci., 2003, 74(1), 55-73. (Pubitemid 37324220)
108. Zhang, W.; Li, J.; Zhu, J.; Shi, Z.; Wang, Y.; Kong, L. Chinese medicine banxia-houpu decoction regulates c-fos expression in the brain regions in chronic mild stress model in rats. Phytother. Res., 2004, 18, 200-203. (Pubitemid 38568745)
109. Ikeya, Y.; Takeda, S.; Tunakawa, M.; Karakida, H.; Toda, K.; Yamaguchi, T.; Aburada, M. Cognitive improving and cerebral protective effects of acylated oligosaccharides in Polygala tenuifolia. Biol. Pharmacol. Bull., 2004, 27(7), 1081-1085. (Pubitemid 41701763)
110. Liu, P.; Hu, Y.; Guo, D.H.; Wang, D.X.; Tu, H.H.; Ma, L.; Xie, T.T.; Kong, L.Y. Potential antidepressant properties of Radix polygalae (Yuan Zhi). Phytomedicine, 2010 Aug, 17(10), 794-799.
111. Hu, Y.; Liu, M.; Liu, P.; Guo, D.H.; Wei, R.B.; Rahman, K. Possible mechanisms of the antidepressant effect of 3,6'-disinapoyl sucrose from Polygala tenuifolia Wild. J. Pharm. Pharmacol., 2011, 63(6), 869-874.
112. Hu, Y.; Liu, P.; Gui, D.H.; Rahman, K.; Wang, D.X.; Xie, T.T. Antidepressant effects of the extract YZ-50 from Polygala tenuifolia in chronic mild stress treated rats and its possible mechanisms. Pharm. Biol., 2010, 48(7), 794-800.
113. Nagai, T.; Suzuki, Y.; Kiyohara, H.; Susa, E.; Kato, T.; Nagamine, T.; Hagiwara, Y.; Tamura, S.; Yabe, T.; Aizawa, C.; Yamada, H. Onjisaponins, from the root of Polygala tenuifolia Willdenow, as effective adjuvants for nasal influenza and diphtheria-pertussis-tetanus vaccines. Vaccine, 2001, 19(32), 4824-4834. (Pubitemid 32800769)
114. Wang, Z.; Li, H.; Xu, H.; Yue, X.L.; Cheng, X.Q.; Hou, W.J.; Zhang, Y.Y.; Chen, D.F. Beneficial effect of Bupleurum polysaccharides on autoimmune disease induced by Campylobacter jejuni in BALB/c mice. J. Ethnopharmacol., 2009, 124(3), 481-7.
115. Chiang, L.-C.; Ng, L.T.; Liu, L.T.; Shieh, D.; Lin,C.-C. Cytotoxicity and anti-hepatitis B virus activities of saikosaponins from Bupleurum species. Planta Med., 2003, 69(8), 705-709. (Pubitemid 37215018)
116. Kojima, H.; Yanai, T.; Toyota, A. Essential oil constituents from Japanese and Indian Curcuma aromatica rhizomes. Planta Med., 1998, 64(4), 380-381. (Pubitemid 28234283)
117. Choochote, W.; Chaiyasit, D.; Kanjanapothi, D.; Rattanachanpichai, E.; Jitpakdi, A.; Tuetun, B.; Pitasawat, B. Chemical composition and antimosquito potential of rhizome extract and volatile oil derived from Curcuma aromatica against Aedes aegypti (Diptera: Culicidae). J. Vector Ecol., 2005, 30(2), 302-309. (Pubitemid 43355888)
118. Deng, C.; Li, N.; Zhang, X. Rapid determination of essential oil in Acorus tatarinowii Schott. by pressurized hot water extraction followed by solidphase microextraction and gas chromatography-mass spectrometry. J. Chromatogr. A, 2004,1059, 149-155. (Pubitemid 39539773)
119. Wei, G.; Fang, Y.Q.; Liu, D.H.; Lin, S.F. [Study on GC-MS fingerprint analysis in rhizome of volatile oil of Acorus tatarinowii]. Zhongguo Zhong Yao Za Zhi, 2004, 29(8), 764-768.
120. Mao, Q.Q.; Zhong, X.M.; Li, Z.Y.; Feng, C.R.; Pan, A.J.; Huang, Z. Herbal formula SYJN increases neurotrophin 3 and nerve growth factor expression in brain regions of rats exposed to chronic unpredictable stress. J. Ethnopharmacol., 2010, 13(1), 182-186.
121. Khan, I.A.; Abourashed, E.A. Leung's Encyclopedia of Common Natural Ingredients Used in Foods, Drugs and Cosmetics, 3rd ed., Wiley, New Jersey, 2009, pp. 415-420.
122. Khan, I.A.; Abourashed, E.A. Leung's Encyclopedia of Common Natural Ingredients Used in Foods, Drugs and Cosmetics, 3rd ed., Wiley, New Jersey, 2009, pp. 388-389.
123. Lou, J.S.; Li, C.Y.; Yang, X.X.; Fang, J.; Yang, Y.X.; Guo, J.Y. Protective effect of gan mai da zao decoction in unpredictable chronic mild stressinduced behavioral and biochemical alterations. Pharm Biol, 2010, 48(12), 1328-1336.
124. Ahmed, S.A.; Ross, S.A.; Slade, D.; Radwan, M.; Zulfiqar, F.; ElSohly, M.A. Cannabinoid ester constituents from high potency Cannabis sativa L. J. Nat. Prod., 2008, 71, 536-542. (Pubitemid 351656182)
125. Ahmed, S.A.; Ross, S.A.; Slade, D.; Radwan, M.M.; Khan, I.A.; ElSohly, M.A. Absolute configuration of cannabichromene derivatives from high potency Cannabis sativa. Tetrahedron Lett., 2008, 49, 6050-6053.
126. ElSohly, M.A.; Slade, D. Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sci., 2005, 78:539-548. (Pubitemid 41653504)
127. Skolnick, P.; Legutko, B.; Li, X.; Bymaster, F. Current perspectives on the development of non biogenic amine-based antidepressants. Pharmacol. Res., 2001, 43, 411-412.
128. Grinsponn, L.; Balkar, J. The use of cannabis as a mood stabilizer in bipolar disorder: Anecdotal evidence and the need for clinical research. J. Psychoactive Drugs, 1998, 30:171-177.
129. Gruber, A.; Pope, H.; Brown, M. Do patients use marijuana as an antidepressant? Depression, 1996, 4:77-80. (Pubitemid 27099514)
130. Johns, A. The psychiatric effects of cannabis. Br. J. Psychiatry, 2001, 178, 116-122.
131. Devane, W.; Hanus, L.; Breuer, A.; Pertwee, R.; Stevenson, L.; Griffin, G.; Gibson, D.; Manelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptors. Science, 1992, 258:1946-1949. (Pubitemid 23026736)
132. Dinh, T.; Carpenter, D.; Leslie, F.; Freund, T.; Katona, I.; Sensi, S.; Kathuria ,S.; Piomelli, D. Brain monoglyceride lipase participating in endocannabinoid inactivation. PNAS, 2002, 99:10819-10824.
133. Gong, J.; Onaivi, E.; Ishigura, H.L.Q.; Tagliaferro, P.; Brusco, A.; Uhi, G. Cannabinoid CB2 receptors immunohistochemical localization in rat brain. Brain Res., 2006, 1071(1):10-23. (Pubitemid 43255471)
134. Okamoto, Y.; Morishita, J.; Tsuboi, K.; Tonai, T.; Ueda, N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J. Biol. Chem., 2004, 279, 5298-5305. (Pubitemid 38220550)
135. El-Alfy, A.T.; Ivey, K.; Robinson, K.; Ahmed, S.; Radwan, M.; Slade, D.; Khan, I.; ElSohly, M.; Ross, S. Antidepressant-like effects of ?9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol. Biochem. Behav., 2010, 95, 434-442.
136. Degenhardt, L.; Hall, W.; Lynskey, M. Exploring the association between cannabis use and depression. Addiction, 2003, 98: 1493-1504. (Pubitemid 37373847)
137. Doggrell, S.A. Is rimonabant efficacious and safe in the treatment of obesity? Expert Opin. Pharmacother., 2008, 9: 2727-2731.
138. Maplestone, R.A.; Stone, M.J.; Williams, D.H. The evolutionary role of secondary metabolites -A review. Gene, 1992, 115:151-157.
139. Amsler, C.D.; McClintock, J.B.; Baker, B.J. Secondary metabolites as mediators of trophic interactions among antarctic marine organisms. Amer. Zoo., 2001, 41, 17-26.
140. Paul V.J. Ecological roles of marine natural products. In: Paul VJ, editor. Ithica: Comstock Publishing Associates; 1992, pp. 1-23.
141. Gavagnin, M.; Fontana, A. Diterpenes from marine opisthobranch molluscs. Curr. Org. Chem., 2000, 4(12), 1201-1248. (Pubitemid 32045645)
142. Haefner B. Drugs from the deep: Marine natural products as drug candidates. Drug. Disc. Today, 2003, 8, 536-544. (Pubitemid 36773671)
143. Sipkema, D.; Franssen, M.C.R.; Osinga, R.; Tramper, J.; Wijffels, R.H. Marine sponges as pharmacy. Mar. Biotech., 2005, 7:142-162. (Pubitemid 41187741)
144. Diers, J.A.; Ivey, K.; El-Alfy, A.T.; Shaikh, J.; Wang, J.; Kochanowska, A.J.; Stoker, J.F.; Hamann, M.T.; Matsumoto, R.R. Identification of antidepressant drug leads through the evaluation of marine natural products with neuropsychiatric pharmacophores. Pharmacol. Biochem. Behav., 2008, 89, 46-53.
145. Kochanowska, A.J.; Rao, K.V.; Childress, S.; El-Alfy, A.T.; Matsumoto, R.R.; Kelly, M.; Stewart, G.S.; Sufka, K.J.; Hamann, M.T. Secondary metabolites from three Florida sponges with antidepressant activity. J. Nat. Prod., 2008, 71, 186-189. (Pubitemid 351362975)